

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

Market Report | 2024-11-15 | 498 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period.

Factors such as advancements in gene editing technologies, and the expanding range of gene editing applications are driving the growth of the gene editing market. However, the market faces several challenges due to off-target effects of gene editing, along with difficulties in scalability and manufacturing, pose significant hurdles.

"The product segment accounted for the largest share by offerings segment in the gene editing market in 2023"

By offerings, the gene editing market is segmented into products and services. The products segment held the largest share in 2023. The demand for products in gene editing process including experimentation and research for cell line development and drug development & discovery make them an indispensable part of the gene market. Gene editing products as reagents & consumables and Software & systems like gene editing kits, gene editing reagents and gene editing libraries are utilized by pharmaceutical & biotechnology companies and academic & research institutes in various gene editing workflow. Services held the second highest share of the gene editing market in 2023.

"The CRISPR technology held the highest market share of the gene editing products market by technology in 2023"

By Technology, the gene editing products market is segmented into CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies which include piggybac and prime editing among others. The CRISPR segment held the highest share of the gene editing products by technology market in 2023 driven by advancements in CRISPR technology leading to large scale adoption of this technology in gene editing. Gene editing products are used in a large range of CRISPR applications including reagents like

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Cas-9, vectors, libraries for screening and target identification and CRISPR based gene editing kits. Still, TALEN segment held the second largest share of the market in 2023.

"The Asia Pacific region is growing at the highest CAGR in the gene editing market from 2024 to 2029."

The Asia Pacific is estimated to be the fastest-growing segment of the market owing to the a significant focus on R&D activities, funding by government and private players in gene editing research, and rising adoption of gene editing technologies in drug discovery & development. Further, the rising prevalence of rare and genetic diseases is attributed to the aging population of countries such as Japan, and China. This is supporting the adoption of gene editing technologies in healthcare management and treatment driving the market growth. However, North America held the largest share of gene editing market in 2023.

The primary interviews conducted for this report can be categorized as follows:

-□By Respondent: Supply Side- 70% and Demand Side 30%

-□By Designation: Managers - 45% CXOs and Director-level - 30%, and Executives - 25%,

-□By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5%, and Middle East -5%.

List of Companies Profiled in the Report:

-□Thermo fisher scientific Inc. (US)

-□Merck KGaA (Germany)

-□GenScript (US)

-□Agilent Technologies, Inc. (US)

-□Revvity (US)

-□ Lonza (US)

-□Tecan Trading AG (Switzerland)

-□Sangamo therapeutics (US)

-□Precision BioSciences (US)

-□Cellestis S.A. (France)

-□Regeneron Pharmaceuticals Inc. (US)

-□AMSBIO (UK)

-□Creative Biogene (US)

-□Synthego (US)

-□Takara Bio Inc. (Japan)

-□Bio-Techne (US)

-□Caribou Biosciences, Inc. (US)

-□Bioneer corporation (South Korea)

-□REPROCELL Inc. (Japan)

Research Coverage:

This research report categorizes the gene editing market by offerings (products and services), products by type (reagents & consumables, and software & systems), reagents & consumables by Technique (knock-out, knock-in, gene silencing, and other techniques), products by technology (CRISPR, TALEN, ZFN, Base editing, Antisense, RNAi and other technologies), products by application (cell line engineering, genome editing/genetic engineering, drug discovery & development, and other applications), products by end user (pharmaceutical & biotechnology companies, academic & research institutes, CROs & CDMOs, and other end users), services by type (cell line engineering, gRNA synthesis & vector construction, library construction & screening, and other types), services by application (cell line development & engineering, genome editing/genetic engineering, drug discovery & development, and other applications), services by end user (pharmaceutical & biotechnology companies, academic & research institutes, and other end users) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

restraints influencing the growth of the genomics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product & service portfolio, key strategies such as product & service launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the gene editing market. Competitive analysis of top players and upcoming startups in the gene editing market ecosystem is covered in this report.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall gene editing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Increasing demand for personalized medicine, Favorable government funding investments for gene editing projects, Expanding applications of gene editing), restraints (Off-Target Effects and Safety Concerns), opportunities (Technological advancements in Prime editing and bridge RNA, Rising burden of congenital disorders), and challenges (Issues with scalability of gene editing workflows. High equipment and facility costs) influencing the growth of the market.

-□Product Development/Innovation: Detailed insights on newly launched product/services of the gene editing market

-□Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.

-□Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the gene editing market

-□Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US), Lonza (US), Tecan Trading AG (Switzerland), Sangamo therapeutics (US), Precision BioSciences (US), Collectis S.A. (France), Regeneron Pharmaceuticals Inc. (US), AMSBIO (UK), Creative Biogene (US), Synthego (US), Takara Bio Inc. (Japan), Bio-Techne (US), Caribou Biosciences, Inc. (US) Bioneer corporation (South Korea), and REPROCELL Inc. (Japan).

Table of Contents:

1	INTRODUCTION	43
1.1	STUDY OBJECTIVES	43
1.2	MARKET DEFINITION	43
1.3	STUDY SCOPE	44
1.3.1	MARKETS COVERED	44
1.3.2	INCLUSIONS & EXCLUSIONS	45
1.3.3	YEARS CONSIDERED	46
1.3.4	CURRENCY CONSIDERED	46
1.4	LIMITATIONS	46
1.5	STAKEHOLDERS	46
1.6	SUMMARY OF CHANGES	47
2	RESEARCH METHODOLOGY	48
2.1	RESEARCH DATA	48
2.1.1	SECONDARY DATA	49
2.1.2	PRIMARY DATA	50
2.2	MARKET ESTIMATION METHODOLOGY	51
2.2.1	MARKET ESTIMATION	51
2.2.1.1	Insights of primary experts	53
2.2.2	SEGMENTAL MARKET SIZE ESTIMATIONS	54
2.3	MARKET GROWTH RATE PROJECTIONS	55
2.4	MARKET BREAKDOWN AND DATA TRIANGULATION	57
2.5	RESEARCH ASSUMPTIONS	58

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

2.6	RESEARCH LIMITATIONS	58
2.7	RISK ANALYSIS	59
3	EXECUTIVE SUMMARY	60
4	PREMIUM INSIGHTS	66
4.1	GENE EDITING MARKET OVERVIEW	66
4.2	NORTH AMERICA: GENE EDITING MARKET, BY TYPE AND COUNTRY (2023)	67
4.3	GENE EDITING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES	67
5	MARKET OVERVIEW	68
5.1	INTRODUCTION	68
5.2	MARKET DYNAMICS	68
5.2.1	DRIVERS	69
5.2.1.1	Increasing demand for personalized medicine	69
5.2.1.2	Favorable government funding investments for gene editing projects	71
5.2.1.3	Expanding applications of gene editing	72
5.2.2	RESTRAINTS	72
5.2.2.1	Off-target effects and safety concerns	72
5.2.3	OPPORTUNITIES	73
5.2.3.1	Rising technological advancements in prime editing and bridge RNA	73
5.2.3.2	Increasing burden of congenital disorders	73
5.2.4	CHALLENGES	74
5.2.4.1	Issues associated with scalability of gene editing workflows	74
5.2.4.2	High equipment & manufacturing costs	74
5.3	TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES	75
5.4	PRICING ANALYSIS	76
5.4.1	AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY CONSUMABLE (2023)	76
5.4.2	AVERAGE COST RANGE OF GENE EDITING KITS & REAGENTS, 2021?2023	77
5.4.3	AVERAGE SELLING PRICE TREND OF SERVICES, BY TYPE	78
5.4.4	AVERAGE SELLING PRICE, BY REGION	79
5.5	SUPPLY CHAIN ANALYSIS	81
5.6	VALUE CHAIN ANALYSIS	82
5.7	ECOSYSTEM ANALYSIS	86
5.8	IMPACT OF GENERATIVE AI ON GENE EDITING MARKET	87
5.9	TECHNOLOGY ANALYSIS	89
5.9.1	KEY TECHNOLOGIES	89
5.9.1.1	Next-generation sequencing	89
5.9.1.2	Electroporation	89
5.9.1.3	Microinjection	89
5.9.2	COMPLEMENTARY TECHNOLOGIES	90
5.9.2.1	Synthetic biology	90
5.9.2.2	Data analysis	90
5.9.2.3	High-throughput screening	91
5.9.3	ADJACENT TECHNOLOGIES	91
5.9.3.1	Single-cell analysis	91
5.9.3.2	Optogenetics	92
5.9.3.3	Gene delivery systems	92
5.10	PATENT ANALYSIS	92
5.11	KEY CONFERENCES AND EVENTS, 2024?2025	94

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

5.12	REGULATORY ANALYSIS	95
5.12.1	REGULATORY LANDSCAPE	95
5.12.1.1	North America	96
5.12.1.1.1	US	96
5.12.1.1.2	Canada	96
5.12.1.2	Europe	97
5.12.1.2.1	UK	97
?		
5.12.1.3	Asia Pacific	98
5.12.1.3.1	China	98
5.12.1.3.2	Japan	98
5.12.1.3.3	South Korea	98
5.12.1.3.4	Australia	99
5.12.1.3.5	Rest of Asia Pacific	99
5.12.2	REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS	100
5.13	PORTER'S FIVE FORCES ANALYSIS	102
5.13.1	THREAT OF NEW ENTRANTS	103
5.13.2	THREAT OF SUBSTITUTES	103
5.13.3	BARGAINING POWER OF BUYERS	103
5.13.4	BARGAINING POWER OF SUPPLIERS	103
5.13.5	INTENSITY OF COMPETITIVE RIVALRY	104
5.14	KEY STAKEHOLDERS AND BUYING CRITERIA	104
5.14.1	KEY STAKEHOLDERS IN BUYING PROCESS	104
5.14.2	KEY BUYING CRITERIA	105
5.15	CASE STUDY ANALYSIS	105
5.15.1	ENHANCED GENE KNOCK-IN EFFICIENCY USING HYBRID SSDNA HDR TEMPLATES IN PRIMARY HUMAN T-CELLS	105
5.15.2	GENE EDITING EFFICIENCY IN CANCER CELL LINES AND T-CELLS USING TRUECUT CAS9 PROTEIN V2 AND TRUEGUIDE SGRNA	106
5.15.3	DEVELOPMENT & SPECIFICITY OPTIMIZATION OF PURETIT CRISPR CAS9 RNP SYSTEM	106
5.15.4	EVALUATION OF SUREGUIDE CAS9 PROGRAMMABLE NUCLEASE KIT FOR EFFICIENT IN VITRO GENE EDITING	106
5.15.5	GENE EDITING FOR SICKLE-CELL DISEASE USING ZINC FINGER NUCLEASE-MODIFIED HEMATOPOIETIC STEM CELLS	107
5.16	INVESTMENT & FUNDING SCENARIO	107
5.16.1	KEY INVESTMENTS & FUNDING ACTIVITIES, 2021?2024	107
5.17	TRADE DATA ANALYSIS	110
5.17.1	IMPORT DATA, 2019?2023	110
5.17.2	EXPORT DATA, 2019?2023	111
6	GENE EDITING MARKET, BY OFFERING	112
6.1	INTRODUCTION	113
6.2	PRODUCTS	113
6.2.1	EXPANDING APPLICATIONS OF GENE MODIFICATION TECHNIQUES TO DRIVE MARKET	113
6.3	SERVICES	117
6.3.1	HIGH UPTAKE BY PHARMA COMPANIES FOR DRUG DISCOVERY & DEVELOPMENT TO PROPEL MARKET	117
?		
7	GENE EDITING PRODUCTS MARKET, BY TYPE	121
7.1	INTRODUCTION	122
7.2	REAGENTS & CONSUMABLES	122

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

7.2.1	GENE EDITING KITS	126
7.2.1.1	Increasing demand for mutation & screening kits in clinical settings to propel market	126
7.2.2	GENE EDITING LIBRARIES	130
7.2.2.1	Genetic screening for cancer research to fuel uptake	130
7.2.3	GENE EDITING REAGENTS	133
7.2.3.1	Ability to create animal models to support market growth	133
7.3	SOFTWARE & SYSTEMS	137
7.3.1	INTEGRATION OF CLOUD-BASED PLATFORMS FOR NGS TO DRIVE MARKET	137
8	GENE EDITING REAGENTS & CONSUMABLES MARKET, BY TECHNIQUE	141
8.1	INTRODUCTION	142
8.2	KNOCK-OUT	142
8.2.1	MODIFICATION OF CRISPR-CAS9 AND TALENS TO PROPEL MARKET	142
8.3	KNOCK-IN	146
8.3.1	UTILIZATION OF DONOR DNA TEMPLATES AND HDR PATHWAYS TO DRIVE MARKET	146
8.4	GENE SILENCING	149
8.4.1	ADVANCEMENTS IN RNAI TECHNOLOGY AND ANTISENSE THERAPY TO SUPPORT MARKET GROWTH	149
8.5	OTHER TECHNIQUES	153
9	GENE EDITING PRODUCTS MARKET, BY TECHNOLOGY	156
9.1	INTRODUCTION	157
9.2	CRISPR	157
9.2.1	ADVANCEMENTS IN CAS9 PROTEINS TO FUEL UPTAKE	157
9.3	TALENS	161
9.3.1	INCREASING DEMAND FOR THERAPEUTIC DEVELOPMENT TO DRIVE MARKET	161
9.4	ZFN	164
9.4.1	PROVISION OF CUSTOMIZED DESIGN AND TARGETED EDITS TO BOOST DEMAND	164
9.5	BASE EDITING	167
9.5.1	GROWING APPLICATIONS IN FUNCTIONAL GENOMICS TO FUEL MARKET	167
9.6	ANTISENSE	171
9.6.1	INNOVATIONS IN OLIGONUCLEOTIDE THERAPIES TO SUPPORT MARKET GROWTH	171
9.7	RNAI	174
9.7.1	WIDE APPLICATIONS IN DRUG DISCOVERY TO FUEL UPTAKE	174
9.8	OTHER TECHNOLOGIES	177
10	GENE EDITING PRODUCTS MARKET, BY APPLICATION	180
10.1	INTRODUCTION	181
10.2	CELL LINE ENGINEERING	181
10.2.1	ABILITY TO PROVIDE PRECISE GENE MODIFICATIONS FOR VALIDATION TO DRIVE MARKET	181
10.3	GENOME EDITING	185
10.3.1	GROWING APPLICATIONS IN BIOTECHNOLOGY TO BOOST DEMAND	185
10.4	DRUG DISCOVERY & DEVELOPMENT	188
10.4.1	UPTAKE OF CRISPR-BASED SYSTEMS FOR DISEASE PROFILING TO DRIVE MARKET	188
10.5	OTHER APPLICATIONS	192
11	GENE EDITING PRODUCTS MARKET, BY END USER	195

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.1	INTRODUCTION	196
11.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	196
11.2.1	INCREASING PRODUCT APPROVALS AND ROBUST CLINICAL PIPELINE TO PROPEL MARKET	196
11.3	ACADEMIC & RESEARCH INSTITUTES	200
11.3.1	FAVORABLE FUNDING FOR GENOMIC PROJECTS TO DRIVE MARKET	200
11.4	CROS & CMOS	203
11.4.1	PROVISION OF SPECIALIZED EXPERTISE FOR CLINICAL TRIALS TO DRIVE MARKET	203
11.5	OTHER END USERS	206
12	GENE EDITING SERVICES MARKET, BY TYPE	210
12.1	INTRODUCTION	211
12.2	CELL LINE DEVELOPMENT & ENGINEERING	211
12.2.1	GROWING DEMAND FOR BIOLOGICS AND BIOSIMILARS TO DRIVE MARKET	211
12.3	GRNA SYNTHESIS & VECTOR CONSTRUCTION	215
12.3.1	ADVANCEMENTS IN GENE EDITING TECHNOLOGIES AND DEMAND FOR PRECISE TARGETING TO DRIVE MARKET	215
12.4	LIBRARY CONSTRUCTION & SCREENING	218
12.4.1	INCREASING FOCUS ON HIGH-THROUGHPUT SCREENING TO PROPEL MARKET	218
12.5	OTHER SERVICES	222
12.5.1	OTHER SERVICES INCLUDE OFF-TARGET ANALYSIS AND MUTAGENESIS SERVICES.	222
13	GENE EDITING SERVICES MARKET, BY APPLICATION	226
13.1	INTRODUCTION	227
13.2	CELL LINE ENGINEERING	227
13.2.1	HIGH UPTAKE IN R&D FOR THERAPEUTIC BIOPRODUCTION TO DRIVE MARKET	227
13.3	GENOME EDITING	231
13.3.1	GROWING FOCUS ON SYNTHETIC GENOMICS TO BOOST DEMAND	231
13.4	DRUG DISCOVERY & DEVELOPMENT	234
13.4.1	GROWING DEMAND FOR PHARMACEUTICAL DEVELOPMENT TO FUEL UPTAKE	234
13.5	OTHER APPLICATIONS	238
14	GENE EDITING SERVICES MARKET, BY END USER	242
14.1	INTRODUCTION	243
14.2	PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES	243
14.2.1	GROWING DEMAND FOR ADVANCED MODALITIES TO DRIVE MARKET	243
14.3	ACADEMIC & RESEARCH INSTITUTES	247
14.3.1	INCREASING FUNDING FOR GENOMIC PROJECTS TO PROPEL MARKET	247
14.4	OTHER END USERS	250
15	GENE EDITING MARKET, BY REGION	254
15.1	INTRODUCTION	255
15.2	NORTH AMERICA	256
15.2.1	MACROECONOMIC OUTLOOK FOR NORTH AMERICA	261
15.2.2	US	262
15.2.2.1	Growing investments by government authorities and private players to drive market	262
15.2.3	CANADA	266
15.2.3.1	Rise in research & development initiatives for genomics and biotechnology to augment growth	266
15.3	EUROPE	271
15.3.1	MACROECONOMIC OUTLOOK FOR EUROPE	276
15.3.2	GERMANY	278

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.3.2.1 Growing focus on promoting innovations in biotechnology sector to boost market 278
- 15.3.3 FRANCE 283
 - 15.3.3.1 Ongoing clinical trials and advanced genomic research to promote growth 283
 - 15.3.4 UK 287
 - 15.3.4.1 Growing focus on developing cell and gene therapy infrastructure to fuel market 287
 - 15.3.5 ITALY 292
 - 15.3.5.1 Increasing availability of research funds to expedite growth 292
 - 15.3.6 SPAIN 296
 - 15.3.6.1 Booming biotechnology sector to contribute to market growth 296
 - 15.3.7 REST OF EUROPE 301
- 15.4 ASIA PACIFIC 306
 - 15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 311
 - 15.4.2 CHINA 312
 - 15.4.2.1 Increasing affordability of sequencing platforms and procedures to favor growth 312
 - ?
 - 15.4.3 JAPAN 316
 - 15.4.3.1 Growing focus on cancer research to fuel market 316
 - 15.4.4 INDIA 321
 - 15.4.4.1 Increased awareness about therapeutic benefits of genome engineering to encourage growth 321
 - 15.4.5 SOUTH KOREA 326
 - 15.4.5.1 Rising inclination toward in vivo gene editing to stimulate growth 326
 - 15.4.6 AUSTRALIA 330
 - 15.4.6.1 Favorable regulatory landscape to sustain growth 330
 - 15.4.7 REST OF ASIA PACIFIC 335
 - 15.5 LATIN AMERICA 339
 - 15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 344
 - 15.5.2 BRAZIL 345
 - 15.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market 345
 - 15.5.3 REST OF LATIN AMERICA 349
 - 15.6 MIDDLE EAST 353
 - 15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 354
 - 15.6.2 GCC COUNTRIES 359
 - 15.6.2.1 Kingdom of Saudi Arabia 364
 - 15.6.2.1.1 Increasing establishment of biotech startups to support market growth 364
 - 15.6.2.2 United Arab Emirates (UAE) 368
 - 15.6.2.2.1 Growing collaborations for genome sequencing to drive market 368
 - 15.6.2.3 Other GCC Countries 373
 - 15.6.3 REST OF MIDDLE EAST 377
 - 15.7 AFRICA 382
 - 15.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH 382
 - 15.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 386
 - 16 COMPETITIVE LANDSCAPE 388
 - 16.1 INTRODUCTION 388
 - 16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2024 388

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

16.3	REVENUE ANALYSIS, 2019?2023	392
16.4	MARKET SHARE ANALYSIS, 2023	394
16.4.1	RANKING OF KEY MARKET PLAYERS	395
16.5	COMPANY VALUATION AND FINANCIAL METRICS	396
16.5.1	COMPANY VALUATION	396
16.5.2	FINANCIAL METRICS	396
16.6	BRAND/PRODUCT COMPARISON	397
16.6.1	THERMO FISHER SCIENTIFIC INC. (US)	397
16.6.2	MERCK KGAA (GERMANY)	397
16.6.3	GENSCRIPT (US)	398
16.6.4	AGILENT TECHNOLOGIES, INC. (US)	398
16.6.5	REVVITY, INC. (US)	398
16.7	COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023	398
16.7.1	STARS	398
16.7.2	EMERGING LEADERS	398
16.7.3	PERVASIVE PLAYERS	398
16.7.4	PARTICIPANTS	399
16.7.5	COMPANY FOOTPRINT: KEY PLAYERS, 2023	400
16.7.5.1	Company footprint	400
16.7.5.2	Product footprint	401
16.7.5.3	Service footprint	402
16.7.5.4	Technology footprint	403
16.7.5.5	Region footprint	405
16.8	COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023	406
16.8.1	PROGRESSIVE COMPANIES	406
16.8.2	RESPONSIVE COMPANIES	406
16.8.3	DYNAMIC COMPANIES	406
16.8.4	STARTING BLOCKS	406
16.8.5	COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023	408
16.8.5.1	Detailed list of key startups/SMEs	408
16.8.5.2	Competitive benchmarking of key startups/SMEs	409
16.9	COMPETITIVE SCENARIO	409
16.9.1	PRODUCT/SERVICE LAUNCHES & APPROVALS	410
16.9.2	DEALS	411
16.9.3	EXPANSIONS	413
17	COMPANY PROFILES	414
17.1	KEY PLAYERS	414
17.1.1	THERMO FISHER SCIENTIFIC INC.	414
17.1.1.1	Business overview	414
17.1.1.2	Products/Services offered	415
17.1.1.3	Recent developments	417
17.1.1.3.1	Product/Service launches & approvals	417
17.1.1.3.2	Deals	417
17.1.1.3.3	Expansions	418
17.1.1.4	MnM view	418
17.1.1.4.1	Key strengths	418
17.1.1.4.2	Strategic choices	418

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1.1.4.3 Weaknesses & competitive threats 418
- ?
- 17.1.2 MERCK KGAA 419
- 17.1.2.1 Business overview 419
- 17.1.2.2 Products/Services offered 420
- 17.1.2.3 Recent developments 422
- 17.1.2.3.1 Deals 422
- 17.1.2.4 MnM view 422
- 17.1.2.4.1 Key strengths 422
- 17.1.2.4.2 Strategic choices 422
- 17.1.2.4.3 Weaknesses & competitive threats 423
- 17.1.3 GENSCRIPT 424
- 17.1.3.1 Business overview 424
- 17.1.3.2 Products/Services offered 425
- 17.1.3.3 Recent developments 427
- 17.1.3.3.1 Product/Service launches & approvals 427
- 17.1.3.3.2 Deals 428
- 17.1.3.3.3 Expansions 428
- 17.1.3.4 MnM view 428
- 17.1.3.4.1 Key strengths 428
- 17.1.3.4.2 Strategic choices 429
- 17.1.3.4.3 Weaknesses and competitive threats 429
- 17.1.4 AGILENT TECHNOLOGIES, INC. 430
- 17.1.4.1 Business overview 430
- 17.1.4.2 Products/Services offered 431
- 17.1.4.3 Recent developments 433
- 17.1.4.3.1 Deals 433
- 17.1.4.3.2 Expansions 434
- 17.1.4.4 MnM view 434
- 17.1.4.4.1 Key strengths 434
- 17.1.4.4.2 Strategic choices 434
- 17.1.4.4.3 Weaknesses & competitive threats 434
- 17.1.5 REVVITY, INC. 435
- 17.1.5.1 Business overview 435
- 17.1.5.2 Products/Services offered 436
- 17.1.5.3 Recent developments 439
- 17.1.5.3.1 Product/Service launches 439
- 17.1.5.3.2 Deals 439
- 17.1.5.4 MnM view 440
- 17.1.5.4.1 Key strengths 440
- 17.1.5.4.2 Strategic choices 440
- 17.1.5.4.3 Weakness & competitive threats 440
- ?
- 17.1.6 LONZA 441
- 17.1.6.1 Business overview 441
- 17.1.6.2 Products/Services offered 442
- 17.1.6.3 Recent developments 443

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

17.1.6.3.1 Product/Service launches 443
17.1.7 TECAN TRADING AG 444
17.1.7.1 Business overview 444
17.1.7.2 Products/Services offered 445
17.1.7.3 Recent developments 446
17.1.7.3.1 Deals 446
17.1.8 SANGAMO THERAPEUTICS 447
17.1.8.1 Business overview 447
17.1.8.2 Products/Services offered 448
17.1.8.3 Recent developments 448
17.1.8.3.1 Deals 448
17.1.9 PRECISION BIOSCIENCES 449
17.1.9.1 Business overview 449
17.1.9.2 Products/Services offered 450
17.1.9.3 Recent developments 450
17.1.9.3.1 Deals 450
17.1.10 CELLECTIS S.A. 451
17.1.10.1 Business overview 451
17.1.10.2 Products/Services offered 452
17.1.10.3 Recent developments 452
17.1.10.3.1 Deals 452
17.1.11 REGENERON PHARMACEUTICALS, INC. 453
17.1.11.1 Business overview 453
17.1.11.2 Products/Services offered 454
17.1.11.3 Recent developments 454
17.1.11.3.1 Deals 454
17.1.12 AMSBIO 455
17.1.12.1 Business overview 455
17.1.12.2 Products/Services offered 455
17.1.13 CREATIVE BIOGENE 457
17.1.13.1 Business overview 457
17.1.13.2 Products/Services offered 457
17.1.14 SYNTHEGO 460
17.1.14.1 Business overview 460
17.1.14.2 Products/Services offered 460
?
17.1.14.3 Recent developments 462
17.1.14.3.1 Product/Service launches 462
17.1.14.3.2 Deals 462
17.1.14.3.3 Expansions 462
17.1.15 TAKARA BIO INC. 463
17.1.15.1 Business overview 463
17.1.15.2 Products/Services offered 464
17.1.15.3 Recent developments 466
17.1.15.3.1 Deals 466
17.1.15.3.2 Expansions 466
17.1.16 BIO-TECHNE 467

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.1.16.1 Business overview 467
- 17.1.16.2 Products/Services offered 468
- 17.1.16.3 Recent developments 470
 - 17.1.16.3.1 Deals 470
 - 17.1.16.3.2 Expansions 470
- 17.1.17 CARIBOU BIOSCIENCES, INC. 471
 - 17.1.17.1 Business overview 471
 - 17.1.17.2 Products/Services offered 472
 - 17.1.17.3 Recent developments 472
 - 17.1.17.3.1 Deals 472
- 17.1.18 BIONEER CORPORATION 473
 - 17.1.18.1 Business overview 473
 - 17.1.18.2 Products/Services offered 474
- 17.1.19 REPROCELL INC. 475
 - 17.1.19.1 Business overview 475
 - 17.1.19.2 Products/Services offered 476
- 17.2 OTHER PLAYERS 477
 - 17.2.1 ALSTEM INC. 477
 - 17.2.2 NEW ENGLAND BIOLABS 478
 - 17.2.3 INSCRIPTA, INC. 479
 - 17.2.4 BIOCAT GMBH. 480
 - 17.2.5 INTEGRATED DNA TECHNOLOGIES, INC. 481
 - 17.2.6 COBO TECHNOLOGIES APS 482
 - 17.2.7 GENECOPOEIA, INC. 483
 - 17.2.8 HERA BIOLABS 484
 - 17.2.9 STEMCELL TECHNOLOGIES. 485
 - 17.2.10 AXOL BIOSCIENCE LTD. 486
 - 17.2.11 CELLECTA, INC. 487
 - 17.2.12 APPLIED STEMCELL 488
- ?
- 18 APPENDIX 489
 - 18.1 DISCUSSION GUIDE 489
 - 18.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL 494
 - 18.3 CUSTOMIZATION OPTIONS 496
 - 18.4 RELATED REPORTS 496
 - 18.5 AUTHOR DETAILS 497

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

Market Report | 2024-11-15 | 498 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User	\$4950.00
	Multi User	\$6650.00
	Corporate License	\$8150.00
	Enterprise Site License	\$10000.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Zip Code*

Country*

Date

2026-03-03

Signature

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com